Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), developed for type 2 diabetes and obesity, may also reduce alcohol consumption by modulating central reward pathways. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.